Publication
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (51)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 51
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugSunvozertinibcivic_curation1.00
- geneEGFRcivic_curation1.00
- variantEGFR A763_Y764insFQEAcivic_curation1.00
- variantEGFR A767_S768insTLAcivic_curation1.00
- variantEGFR A767_V769dupASVcivic_curation1.00
- variantEGFR C775_R776insNPHVCcivic_curation1.00
- variantEGFR D770delinsAScivic_curation1.00
- variantEGFR D770delinsGYcivic_curation1.00
- variantEGFR D770_N771insDcivic_curation1.00
- variantEGFR D770_N771insFcivic_curation1.00
- variantEGFR D770_N771insGcivic_curation1.00
- variantEGFR D770_N771insGDcivic_curation1.00
- variantEGFR D770_N771insGTcivic_curation1.00
- variantEGFR D770_N771insHcivic_curation1.00
- variantEGFR D770_N771insTcivic_curation1.00
- variantEGFR D770_N771insYcivic_curation1.00
- variantEGFR Exon 20 Insertioncivic_curation1.00
- variantEGFR H773delinsNPYcivic_curation1.00
- variantEGFR H773delinsPNPYcivic_curation1.00
- variantEGFR H773delinsYNPYcivic_curation1.00
- variantEGFR H773delinsYPNPYcivic_curation1.00
- variantEGFR H773_V774insAHcivic_curation1.00
- variantEGFR H773_V774insGNPHcivic_curation1.00
- variantEGFR H773_V774insHcivic_curation1.00
- variantEGFR H773_V774insHPHcivic_curation1.00
- variantEGFR H773_V774insNPHcivic_curation1.00
- variantEGFR H773_V774insPHcivic_curation1.00
- variantEGFR H773_V774insTHcivic_curation1.00
- variantEGFR N771delinsCHcivic_curation1.00
- variantEGFR N771delinsGFcivic_curation1.00
- variantEGFR N771delinsGYcivic_curation1.00
- variantEGFR N771delinsRDcivic_curation1.00
- variantEGFR N771delinsSQRGHcivic_curation1.00
- variantEGFR N771dupcivic_curation1.00
- variantEGFR N771_P772insDNcivic_curation1.00
- variantEGFR N771_P772insRHcivic_curation1.00
- variantEGFR N771_P772insTcivic_curation1.00
- variantEGFR N771_P772insVDNcivic_curation1.00
- variantEGFR P772delinsHRcivic_curation1.00
- variantEGFR P772_H773insDNPcivic_curation1.00
- variantEGFR P772_H773insPHPcivic_curation1.00
- variantEGFR P772_H773insQcivic_curation1.00
- variantEGFR P772_H773insRNPcivic_curation1.00
- variantEGFR P772_H773insYNPcivic_curation1.00
- variantEGFR S768_D770dupcivic_curation1.00
- variantEGFR S768_V769insLDScivic_curation1.00
- variantEGFR V769_D770insCVcivic_curation1.00
- variantEGFR V769_D770insGAcivic_curation1.00
- variantEGFR V769_D770insGVASVcivic_curation1.00
- variantEGFR V774_C775insHVcivic_curation1.00
Curated evidence
Evidence citing this paper (7)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 40923280
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| EGFR A767_S768insTLA + EGFR D770delinsAS + EGFR D770delinsGY + EGFR D770_N771insY + EGFR H773_V774insGNPH + EGFR N771_P772insT + EGFR S768_V769insLDS + EGFR V769_D770insCV + EGFR V769_D770insGA + EGFR V769_D770insGVASV1 | ||||||||
| Sunvozertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12631In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC | civic |
| EGFR D770_N771insD + EGFR D770_N771insF + EGFR D770_N771insGD + EGFR D770_N771insGT + EGFR D770_N771insT + EGFR N771delinsCH + EGFR N771delinsGF + EGFR N771delinsRD + EGFR N771delinsSQRGH + EGFR N771_P772insDN1 | ||||||||
| Sunvozertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12632In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC | civic |
| EGFR Exon 20 Insertion1 | ||||||||
| Sunvozertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12718In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC | civic |
| EGFR C775_R776insNPHVC + EGFR H773delinsYNPY + EGFR H773delinsYPNPY + EGFR H773_V774insHPH + EGFR H773_V774insTH1 | ||||||||
| Sunvozertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12634In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC | civic |
| EGFR A763_Y764insFQEA + EGFR D770_N771insG + EGFR D770_N771insH + EGFR H773_V774insAH + EGFR H773_V774insH + EGFR H773_V774insNPH + EGFR H773_V774insPH + EGFR N771dup + EGFR V774_C775insHV1 | ||||||||
| Sunvozertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12630In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC | civic |
| EGFR H773delinsNPY + EGFR H773delinsPNPY + EGFR N771delinsGY + EGFR N771_P772insRH + EGFR N771_P772insVDN + EGFR P772delinsHR + EGFR P772_H773insDNP + EGFR P772_H773insPHP + EGFR P772_H773insQ + EGFR P772_H773insRNP + EGFR P772_H773insYNP1 | ||||||||
| Sunvozertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12633In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC | civic |
| EGFR A767_V769dupASV + EGFR S768_D770dup1 | ||||||||
| Sunvozertinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | A | Supports Sensitivity Response | 4 | accepted | EID12623In a multinational open label phase II dose randomized study of sunvozertinib in platinum pretreated advanced NSCLC with EGFR exon 20 insertion mutations (WU-KONG1B, NCT03974022; efficacy n = 85 for 2… (full text at CIViC) PMID 40923280 · Yang et al., 2025 · Open in CIViC | civic |